Financials Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Equities
600329
CNE000001808
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.68 CNY | +0.30% |
|
+0.05% | -10.83% |
| Mar. 31 | Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Drops 4.4% in 2025 | MT |
| Mar. 31 | Singapore Shares Remain in Red Amid Soaring Energy Costs; Rex International Plunges 20% | MT |
Projected Income Statement: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 8,249 | 8,222 | 7,307 | 4,917 | 5,348 | 5,797 |
| Change | - | - | -0.33% | -11.14% | -32.7% | 8.76% | 8.4% |
| EBITDA | - | 1,099 | 906.4 | - | - | - | - |
| Change | - | - | -17.52% | - | - | - | - |
| EBIT 1 | - | 980 | 1,097 | 2,567 | 2,490 | 1,295 | 1,426 |
| Change | - | - | 11.93% | 133.98% | -3.01% | -47.98% | 10.12% |
| Interest Paid | - | 39.77 | -24.59 | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | 980.2 | 1,095 | 2,579 | 2,487 | 1,300 | 1,433 |
| Change | - | - | 11.75% | 135.43% | -3.54% | -47.74% | 10.23% |
| Net income 1 | 769.1 | 861.8 | 986.7 | 2,229 | 2,131 | 1,124 | 1,239 |
| Change | - | 12.05% | 14.49% | 125.94% | -4.41% | -47.26% | 10.23% |
| Announcement Date | 3/30/22 | 3/31/23 | 3/29/24 | 3/28/25 | 3/30/26 | - | - |
1CNY in Million
Estimates
Forecast Balance Sheet: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - |
| Announcement Date | 3/30/22 | 3/31/23 | 3/29/24 | 3/28/25 | 3/30/26 | - | - |
Estimates
Cash Flow Forecast: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
| Fiscal Period: December | 2022 | 2023 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| CAPEX 1 | 106.4 | 140.7 | 118.2 | 80 | 78 |
| Change | - | 32.26% | - | -32.33% | -2.5% |
| Free Cash Flow (FCF) 1 | - | - | - | - | - |
| Change | - | - | - | - | - |
| Announcement Date | 3/31/23 | 3/29/24 | 3/30/26 | - | - |
1CNY in Million
Estimates
Forecast Financial Ratios: Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | - | - | 13.32% | 11.02% | - | - | - | - |
| EBIT Margin (%) | - | - | 11.88% | 13.34% | 35.13% | 50.63% | 24.21% | 24.6% |
| EBT Margin (%) | - | - | 11.88% | 13.32% | 35.29% | 50.59% | 24.31% | 24.72% |
| Net margin (%) | - | - | 10.45% | 12% | 30.51% | 43.34% | 21.02% | 21.37% |
| FCF margin (%) | - | - | - | - | - | - | - | - |
| FCF / Net Income (%) | - | - | - | - | - | - | - | - |
Profitability | ||||||||
| ROA | - | - | - | 9.68% | - | - | - | - |
| ROE | - | - | 13.15% | 15.06% | 30.51% | 25.57% | 13.6% | 15% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | - | - | 1.29% | 1.71% | - | 2.4% | 1.5% | 1.35% |
| CAPEX / EBITDA (%) | - | - | 9.68% | 15.53% | - | - | - | - |
| CAPEX / FCF (%) | - | - | - | - | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | - | - | 0.8756 | 0.894 | 1.201 | 0.5987 | 1.68 | 1.83 |
| Change | - | - | - | 2.1% | 34.3% | -50.13% | 180.61% | 8.93% |
| Dividend per Share 1 | - | - | 1.12 | 1.28 | - | - | - | - |
| Change | - | - | - | 14.29% | - | - | - | - |
| Book Value Per Share 1 | - | - | 8.432 | 8.571 | 10.18 | - | - | - |
| Change | - | - | - | 1.65% | 18.83% | - | - | - |
| EPS 1 | - | 1 | 1.11 | 1.28 | 2.9 | 2.77 | 1.46 | 1.61 |
| Change | - | - | 11% | 15.32% | 126.56% | -4.48% | -47.29% | 10.27% |
| Nbr of stocks (in thousands) | - | 773,443 | 773,443 | 770,158 | 770,158 | 770,094 | 770,094 | 770,094 |
| Announcement Date | - | 3/30/22 | 3/31/23 | 3/29/24 | 3/28/25 | 3/30/26 | - | - |
1CNY
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E ratio | 27.9x | 25.3x |
| PBR | - | - |
| EV / Sales | 5.16x | 4.76x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
40.68
Average target price
-
Annual profits - Rate of surprise
- Stock Market
- Equities
- 600329 Stock
- Financials Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Select your edition
All financial news and data tailored to specific country editions
